A possible contributor to erythropoiesis-stimulating agents requirement in hemodialysis: Paraoxonase 1 activity
نویسندگان
چکیده
منابع مشابه
Erythropoiesis stimulating agents: approaches to modulate activity
Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may be required to achieve required hemoglobin levels. Therefore, a need was identified in some anemic pa...
متن کاملResistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
The aim of this study was to evaluate the relationship between arterial microcalcification (AMiC) and erythropoiesis-stimulating agents (ESA) hyporesponsiveness in hemodialysis patients. The presence of AMiC was confirmed by pathologic examination of von Kossa-stained arterial specimens acquired during vascular access surgery. We assessed the ESA hyporesponsiveness index (EHRI), defined as the ...
متن کاملDifferences in Erythrocyte Index and Hyporesponsiveness to Erythropoiesis in Hemodialysis Patients Treated with Different Erythropoiesis-Stimulating Agents
The majority of patients undergoing hemodialysis have anemia due to decreased production of erythropoietin. This condition is referred to as renal anemia, and is a type of normocytic and normochromic anemia. Renal anemia contributes to a worsening of quality of life (QOL) and has a poor prognosis for survival. Clinical use of erythropoiesis-stimulating agents (ESAs) has markedly improved the QO...
متن کاملLow versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
The increased risks of death and adverse events with erythropoiesis-stimulating agent (ESA) therapy targeting a higher hemoglobin level are established. It is uncertain whether the adverse effects of ESA therapy are related to dose and are mitigated when a fixed low ESA dose is used. We conducted a multicenter, prospective randomized open-label, blinded-endpoint (PROBE) trial to evaluate fixed ...
متن کاملErythropoiesis stimulating agents: a personal journey.
I write this editorial in deference to the many experts who devote their careers to this important field. In this editorial, I simply report the journeyman route of a medical oncologist who is desperately trying to improve the outcomes of women suffering from breast cancer. At the end of the 1990s, there was much hope that erythropoie-sis stimulating agents (ESAs) would improve the survival of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Turkish Journal of Internal Medicine
سال: 2021
ISSN: 2687-4245
DOI: 10.46310/tjim.882813